Protein-Functionalized Microgel for Multiple Myeloma Cells’ 3D Culture

Multiple myeloma is a hematologic neoplasm caused by an uncontrolled clonal proliferation of neoplastic plasma cells (nPCs) in the bone marrow. The development and survival of this disease is tightly related to the bone marrow environment. Proliferation and viability of nPCs depend on their interact...

Descripción completa

Detalles Bibliográficos
Autores: Marín Pallá, Juan Carlos, Cordón, Lourdes, Sempere, Amparo, Clara-Trujillo, Sandra|||0000-0002-6455-2993, Gallego-Ferrer, Gloria|||0000-0002-2428-0903, Gómez Ribelles, José Luís|||0000-0001-9099-0885
Tipo de recurso: conjunto de datos
Fecha de publicación:2022
País:España
Institución:Universitat Politècnica de València (UPV)
Repositorio:RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Idioma:inglés
OAI Identifier:oai:riunet.upv.es:10251/189950
Acceso en línea:https://riunet.upv.es/handle/10251/189950
Access Level:acceso abierto
Palabra clave:Multiple myeloma
Microgels
Fibronectin
Bortezomib
Dexamethasone
CIENCIA DE LOS MATERIALES E INGENIERIA METALURGICA
Descripción
Sumario:Multiple myeloma is a hematologic neoplasm caused by an uncontrolled clonal proliferation of neoplastic plasma cells (nPCs) in the bone marrow. The development and survival of this disease is tightly related to the bone marrow environment. Proliferation and viability of nPCs depend on their interaction with the stromal cells and the extracellular matrix components, which also influences the appearance of drug resistance. Recapitulating these interactions in an in vitro culture requires 3D environments that incorporate the biomolecules of interest. In this work, we studied the proliferation and viability of three multiple myeloma cell lines in a microgel consisting of biostable microspheres with fibronectin (FN) on their surfaces. We also showed that the interaction of the RPMI8226 cell line with FN induced cell arrest in the G0/G1 cell cycle phase. RPMI8226 cells developed a significant resistance to dexamethasone, which was reduced when they were treated with dexamethasone and bortezomib in combination.